Afamelanotide in fair-skinned Parkinson’s patients CLINUVEL has launch a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson’s Disease in fair-skinned patients.

CLINUVEL Expands Pharmaceutical Portfolio MELBOURNE, Australia, Nov. 08, 2021 (GLOBE NEWSWIRE) -- CLINUVEL has expanded its pharmaceutical development portfolio with NEURACTHEL®, novel formulations of the melanocortin adrenocorticotropic...